Clinical Trial Search

Primary: Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis. — 400; 378 Participants

Primary: Safety of Trogarzo Given as IV Push Over 30 Seconds — 5; 4; 10 Participants

Primary: Pain Intensity — 2.8; 3.0; 2.8; 3.0 score on a scale — p=0.16

Primary: Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF) — 1.62; 1.87 mm2/year

Primary: All-cause Mortality, as Measured by Follow-up Phone Call or NDI — 373; 374 Participants — p=0.765

Primary: Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28 — 32; 17 Participants — p=0.002

Primary: Number of Participants With Adverse Events (AEs) — 55; 15 Participants

Primary: Change in Weight — 121.5; 125.9; 118; 123.7 kg — p=<0.05

Primary: Safety Run-in Sub-study: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 8; 1 Participants

Primary: Progression-free Survival(PFS) — 5.4; 8.1 months

Primary: Investigator Conspicuity Score Difference in Ureter Between WL and NIR-F at 30 Minutes [Adult (Normal/Mild): WL/NIR-F] — 2.7; 4.3 score on a scale — p=<0.001

Primary: Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90 — 36; 31; 37; 35 Participants — p=0.54

Primary: Fistula Suitability for Dialysis at 6 Months (FSD6) — 74; 76; 21; 43 Participants — p=0.2942

Primary: Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90 — 5; 8; 7; 6 Participants — p=0.96

Primary: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C — -45.58; 3.03 percent change from baseline — p=<.0001